LIQUIDITY (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Jul. 31, 2022 |
Jan. 31, 2022 |
Dec. 31, 2020 |
Sep. 30, 2022 |
Sep. 30, 2021 |
Jun. 30, 2022 |
|
| Net loss | $ (9,831) | $ (7,836) | $ (41,100) | |||
| Net cash used in operating activities | (7,589) | $ (6,341) | (39,600) | |||
| Accumulated deficit | (219,029) | (209,198) | ||||
| Cash and cash equivalents | 154,322 | 150,410 | ||||
| Current liabilities | 2,429 | $ 2,462 | ||||
| July 2022 Financing | ||||||
| Underwriting discounts and commissions expense | $ 800 | |||||
| XOMA (US) LLC [Member] | Phase 2 Clinical Trial RZ358 | Xoma License Agreement [Member] | ||||||
| Milestone closing payment | $ 2,000 | |||||
| XOMA (US) LLC [Member] | Phase 3 Clinical Trial Rz 358 | Xoma License Agreement [Member] | Plan | ||||||
| Milestone closing payment | $ 5,000 | 5,000 | ||||
| ActiveSite Pharmaceuticals, Inc | Development And License Agreement [Member] | ||||||
| Milestone closing payment | $ 1,000 | |||||
| ActiveSite Pharmaceuticals, Inc | Phase 2 Clinical Trial RZ402 | Development And License Agreement [Member] | Plan | ||||||
| Milestone closing payment | $ 3,000 | |||||
| X | ||||||||||
- Definition Amount of milestone payment made during the period. No definition available.
|
| X | ||||||||||
- Definition The costs for underwriter discounts, commissions and other fees. No definition available.
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|